2.50
Hdl Handle:
http://hdl.handle.net/10541/108800
Title:
MMAF for advanced gastric cancer.
Authors:
Anderson, Heather; Scarffe, J Howard; Ranson, Malcolm R; Kamthan, A G; Dougal, Mark; Russell, S A; Wilkinson, M J; Ostick, D G
Abstract:
65 patients with metastatic gastric carcinoma were treated with a combination of methotrexate 1.5 g/m2 with 5-fluorouracil 1.5 g/m2 on day 1 and doxorubicin 30 mg/m2 with mitomycin 4 mg/m2 on day 14. Cycles of chemotherapy were repeated every 4 weeks. The overall response rate was 29% with 6% complete responses and 23% partial responses. Prognostic factors that individually affected response were Karnofsky performance (P less than 0.002), and site of the primary tumour (P less than 0.007). Multivariate analysis showed that only increasing Karnofsky performance (P = 0.01) and disease status (P less than 0.02) (patients with recurrent tumours responding better than patients with postoperative residual disease and those with inoperable disease) were important in predicting response to therapy. The overall median survival was 7 months. All 4 patients with a complete response are alive in remission at 13, 28, 48 and 52 months from the date of starting chemotherapy. Univariate analysis identified increasing Karnofsky performance (P less than 0.0001), response to chemotherapy (P less than 0.02) and higher serum albumin (P less than 0.03) as prognostic indicators for survival. Multivariate analysis, of pretreatment factors and day 14 full blood count showed that only Karnofsky performance (P less than 0.0001) and day 14 platelet count (P less than 0.03) were shown to predict survival, higher platelet values being associated with decreased survival.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
MMAF for advanced gastric cancer. 1991, 27 (10):1234-8 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/108800
PubMed ID:
1835592
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorKamthan, A Gen
dc.contributor.authorDougal, Marken
dc.contributor.authorRussell, S Aen
dc.contributor.authorWilkinson, M Jen
dc.contributor.authorOstick, D Gen
dc.date.accessioned2010-08-02T10:13:33Z-
dc.date.available2010-08-02T10:13:33Z-
dc.date.issued1991-
dc.identifier.citationMMAF for advanced gastric cancer. 1991, 27 (10):1234-8 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1835592-
dc.identifier.urihttp://hdl.handle.net/10541/108800-
dc.description.abstract65 patients with metastatic gastric carcinoma were treated with a combination of methotrexate 1.5 g/m2 with 5-fluorouracil 1.5 g/m2 on day 1 and doxorubicin 30 mg/m2 with mitomycin 4 mg/m2 on day 14. Cycles of chemotherapy were repeated every 4 weeks. The overall response rate was 29% with 6% complete responses and 23% partial responses. Prognostic factors that individually affected response were Karnofsky performance (P less than 0.002), and site of the primary tumour (P less than 0.007). Multivariate analysis showed that only increasing Karnofsky performance (P = 0.01) and disease status (P less than 0.02) (patients with recurrent tumours responding better than patients with postoperative residual disease and those with inoperable disease) were important in predicting response to therapy. The overall median survival was 7 months. All 4 patients with a complete response are alive in remission at 13, 28, 48 and 52 months from the date of starting chemotherapy. Univariate analysis identified increasing Karnofsky performance (P less than 0.0001), response to chemotherapy (P less than 0.02) and higher serum albumin (P less than 0.03) as prognostic indicators for survival. Multivariate analysis, of pretreatment factors and day 14 full blood count showed that only Karnofsky performance (P less than 0.0001) and day 14 platelet count (P less than 0.03) were shown to predict survival, higher platelet values being associated with decreased survival.en
dc.language.isoenen
dc.subjectStomach Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAlopecia-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshLeukopenia-
dc.subject.meshMale-
dc.subject.meshMethotrexate-
dc.subject.meshMiddle Aged-
dc.subject.meshMitomycins-
dc.subject.meshPrognosis-
dc.subject.meshStomach Neoplasms-
dc.titleMMAF for advanced gastric cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.